[go: up one dir, main page]

CO7020851A2 - Proteínas y péptidos modificados - Google Patents

Proteínas y péptidos modificados

Info

Publication number
CO7020851A2
CO7020851A2 CO14029997A CO14029997A CO7020851A2 CO 7020851 A2 CO7020851 A2 CO 7020851A2 CO 14029997 A CO14029997 A CO 14029997A CO 14029997 A CO14029997 A CO 14029997A CO 7020851 A2 CO7020851 A2 CO 7020851A2
Authority
CO
Colombia
Prior art keywords
proteins
modified peptides
peptides
modified
Prior art date
Application number
CO14029997A
Other languages
English (en)
Inventor
Claire Ashman
Mary Birchler
Wildt Rudolf M T De
Claire Holland
Alan Peter Lewis
Peter Morley
Thomas Sandal
Michael Steward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1121226.3A external-priority patent/GB201121226D0/en
Priority claimed from GBGB1121233.9A external-priority patent/GB201121233D0/en
Priority claimed from GBGB1121236.2A external-priority patent/GB201121236D0/en
Priority claimed from PCT/EP2012/064632 external-priority patent/WO2013014208A2/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO7020851A2 publication Critical patent/CO7020851A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
CO14029997A 2011-08-17 2014-02-12 Proteínas y péptidos modificados CO7020851A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161524488P 2011-08-17 2011-08-17
GBGB1121226.3A GB201121226D0 (en) 2011-12-12 2011-12-12 Modified proteins and peptides
GBGB1121233.9A GB201121233D0 (en) 2011-12-12 2011-12-12 Modified proteins and peptides
GBGB1121236.2A GB201121236D0 (en) 2011-12-12 2011-12-12 Proteins and peptides
PCT/EP2012/064632 WO2013014208A2 (en) 2011-07-27 2012-07-25 Antigen binding constructs

Publications (1)

Publication Number Publication Date
CO7020851A2 true CO7020851A2 (es) 2014-08-11

Family

ID=47715521

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14029997A CO7020851A2 (es) 2011-08-17 2014-02-12 Proteínas y péptidos modificados

Country Status (25)

Country Link
US (2) US10808040B2 (es)
EP (3) EP2987806A3 (es)
JP (3) JP6297976B2 (es)
KR (2) KR102143506B1 (es)
CN (2) CN108178800B (es)
AR (1) AR087521A1 (es)
AU (3) AU2012296961B2 (es)
BR (1) BR112014003679B1 (es)
CA (1) CA2845029A1 (es)
CO (1) CO7020851A2 (es)
DO (1) DOP2014000029A (es)
EA (1) EA027160B1 (es)
ES (1) ES2813432T3 (es)
HK (1) HK1214281A1 (es)
IL (1) IL230918A0 (es)
MA (1) MA35428B1 (es)
MX (1) MX2014001883A (es)
MY (1) MY167125A (es)
PE (1) PE20141522A1 (es)
PH (1) PH12014500380A1 (es)
SG (2) SG10201605891TA (es)
TW (1) TW201321405A (es)
UA (1) UA118833C2 (es)
UY (1) UY34254A (es)
WO (1) WO2013024059A2 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP3363812A1 (en) * 2011-06-23 2018-08-22 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
EP4350345A3 (en) * 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
PL2723771T3 (pl) 2011-06-23 2020-04-30 Ablynx Nv Białka wiążące albuminy surowicy
BR122017005075B1 (pt) 2011-06-23 2022-09-20 Ablynx N.V Técnicas para prever, detectar e reduzir interferência de proteína não especifica em ensaios envolvendo domínios variáveis únicos de imunoglobulina
AU2012296961B2 (en) * 2011-08-17 2017-02-16 Glaxo Group Limited Modified proteins and peptides
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CN104781277A (zh) * 2012-09-13 2015-07-15 诺华股份有限公司 具有末端修饰的抗原结合分子
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
WO2015104322A1 (en) * 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
DK3143042T3 (da) * 2014-05-16 2020-08-31 Ablynx Nv Forbedrede variable immunoglobulindomæner
EP3982124A1 (en) 2014-05-16 2022-04-13 Ablynx NV Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
PE20170894A1 (es) * 2014-09-26 2017-07-12 Macrogenics Inc Diacuerpos monovalentes biepecificos que son capaces de unir cd19 y cd3 y usos de los mismos
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
EP3271391A1 (en) * 2015-03-20 2018-01-24 Ablynx N.V. Glycosylated immunoglobulin single variable domains
CN107438620A (zh) 2015-03-31 2017-12-05 韦斯夸尔德有限公司 多肽
DK4089113T3 (da) 2015-03-31 2024-02-05 Sorriso Pharmaceuticals Inc Polypeptider
JP7064670B2 (ja) 2015-03-31 2022-05-11 ソリッソ ファーマシューティカルズ，インク． プロテアーゼで切断可能なリンカーを有するペプチド構築体
CN114106178A (zh) 2015-07-16 2022-03-01 印希比股份有限公司 多价和多特异性结合dr5的融合蛋白
EP4218833A1 (en) 2015-10-01 2023-08-02 Whitehead Institute for Biomedical Research Labeling of antibodies
SG11201803416VA (en) 2015-10-30 2018-05-30 Ablynx Nv Polypeptides against il-23
PL3368579T3 (pl) * 2015-10-30 2022-03-21 F. Hoffmann-La Roche Ag Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania
CN108431039B (zh) * 2015-11-12 2022-06-28 埃博灵克斯股份有限公司 改进的p2x7受体结合剂和包含其的多肽
NO2768984T3 (es) * 2015-11-12 2018-06-09
PT3374392T (pt) 2015-11-13 2022-02-07 Ablynx Nv Domínios variáveis de imunoglobulina que se ligam a albumina sérica melhorados
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
TWI782898B (zh) * 2015-11-18 2022-11-11 美商默沙東有限責任公司 Pd1／ctla4結合劑
KR102194188B1 (ko) 2015-11-18 2020-12-24 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
JP6768800B2 (ja) 2015-11-18 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｔｌａ４結合性物質
CN108473561B (zh) 2015-11-27 2022-12-16 埃博灵克斯股份有限公司 抑制cd40l的多肽
PH12018501155B1 (en) 2015-12-04 2024-06-28 Boehringer Ingelheim Int Biparatopic polypeptides antagonizing wnt signaling in tumor cells
GB201522539D0 (en) 2015-12-21 2016-02-03 Hexcel Composites Ltd Improvements in or relating to electrically conducting materials
BR112018076569A2 (pt) * 2016-06-23 2019-04-02 Ablynx Nv ensaios farmacocinéticos melhorados para domínios variáveis simples de imunoglobulina
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
IL266907B2 (en) 2016-12-07 2024-07-01 Ablynx Nv Immunoglobulin sites with a single variable enhance serum albumin binding
SG11201906341XA (en) 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
LT3571225T (lt) 2017-01-17 2024-11-11 Ablynx Nv Patobulintos serumo albumino rišamosios medžiagos
AU2018241286B2 (en) 2017-03-31 2025-03-13 Ablynx N.V. Improved immunogenicity assays
AR111840A1 (es) 2017-05-31 2019-08-21 Boehringer Ingelheim Int Polipéptidos que antagonizan la señalización wnt en células tumorales
IL273119B2 (en) 2017-09-08 2023-10-01 Maverick Therapeutics Inc Constrained conditionally activated binding proteins
CA3075367A1 (en) 2017-09-27 2019-04-04 Elasmogen Ltd Specific binding molecules
CA3089211A1 (en) * 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US11448651B2 (en) * 2018-07-10 2022-09-20 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-exisiting interactions
CN109096394B (zh) * 2018-09-21 2021-11-05 成都阿帕克生物科技有限公司 一种抗葡萄球菌蛋白a的b亚单位的纳米抗体及核酸分子和应用
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
GB201818460D0 (en) * 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
CN114466864B (zh) 2019-06-21 2024-12-27 索瑞索制药公司 多肽
MX2021015763A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
CR20220136A (es) 2019-10-02 2022-05-27 Boehringer Ingelheim Int Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
AU2020403273A1 (en) * 2019-12-11 2022-06-30 Cullinan Oncology, Inc. Anti-CD19 antibodies and multi-specific binding proteins
EP4073114A4 (en) * 2019-12-11 2024-04-17 Cullinan Oncology, Inc. ANTISERUM ALBUMIN ANTIBODIES
AR121706A1 (es) * 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CN116419925A (zh) 2020-08-17 2023-07-11 武田药品工业有限公司 受限的条件激活的结合蛋白
CN117903303A (zh) * 2020-08-20 2024-04-19 南京融捷康生物科技有限公司 Il-5的结合分子及其应用
US20230312715A1 (en) 2020-09-04 2023-10-05 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding protein constructs with human serum albumin domains
WO2022081460A1 (en) * 2020-10-12 2022-04-21 Janssen Biotech, Inc. Biosynthetic materials and methods for multidirectional biotransportation
CN113307870B (zh) * 2020-10-30 2022-12-23 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
KR20230131210A (ko) 2020-12-14 2023-09-12 다케다 야쿠힌 고교 가부시키가이샤 조건부 이중특이성 결합 단백질
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
MX2023011777A (es) 2021-04-06 2023-11-14 Takeda Pharmaceuticals Co Métodos terapéuticos que usan proteínas de unión activadas condicionalmente restringidas.
US20250026842A1 (en) 2021-11-29 2025-01-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Modified protein or polypeptide
EP4448783A1 (en) 2021-12-13 2024-10-23 Heraeus Medical GmbH Tests and methods for detecting bacterial infection
CN118946580A (zh) * 2022-01-27 2024-11-12 詹森生物科技公司 增强的蛋白质组合物
TW202342521A (zh) 2022-02-23 2023-11-01 日商武田藥品工業股份有限公司 條件性雙特異性結合蛋白
IL318486A (en) 2022-07-27 2025-03-01 Ablynx Nv Polypeptides bind to a specific epitope of the neonatal Fc receptor
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate
CN115819599B (zh) * 2022-11-29 2024-01-16 江苏耀海生物制药有限公司 一种利用重组大肠杆菌分泌表达纳米抗体Cablivi的方法
TW202444749A (zh) 2023-01-09 2024-11-16 美商奧迪希治療公司 抗tnfr2抗原結合蛋白及其用途
US20240368250A1 (en) 2023-02-17 2024-11-07 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2024220763A1 (en) * 2023-04-20 2024-10-24 Xentria, Inc. Methods for detecting an anti-drug antibody (ada) against an anti-tnf alpha antibody
WO2024238790A1 (en) * 2023-05-17 2024-11-21 Odyssey Therapeutics, Inc. Modified single-domain antibodies
WO2025006846A2 (en) 2023-06-29 2025-01-02 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
WO2025049750A1 (en) 2023-08-30 2025-03-06 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof
US20250101075A1 (en) 2023-08-30 2025-03-27 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
SI1517921T1 (sl) * 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CA2608873C (en) * 2005-05-20 2017-04-25 Ablynx Nv Single domain vhh antibodies against von willebrand factor
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP2007008925A (ja) 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
US7989219B2 (en) * 2005-05-31 2011-08-02 Canon Kabushiki Kaisha Bispecific capturing molecule
US20100323905A1 (en) * 2005-09-23 2010-12-23 Academisch Ziekenhuis Leiden Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates
CA2629850A1 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
WO2007063308A2 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
WO2009074634A2 (en) 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2121018A2 (en) * 2006-12-13 2009-11-25 Schering Corporation Treating cancer with anti-igf1r antibody 19d12=sch 717454
CN101802197A (zh) 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法
BRPI0812398A2 (pt) 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
MX2009013137A (es) * 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
CN101977654A (zh) 2008-03-21 2011-02-16 埃博灵克斯股份有限公司 冯威勒布兰特因子特异性结合物及其应用方法
US8020937B2 (en) * 2008-07-31 2011-09-20 Lear Corporation Layered technology for energy management of vehicle seating
JP2011530297A (ja) 2008-08-14 2011-12-22 セファロン・オーストラリア・ピーティーワイ・リミテッド バリアントドメイン抗体
JP5823867B2 (ja) 2008-10-29 2015-11-25 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の製剤
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
SG174862A1 (en) * 2009-04-10 2011-11-28 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder
HUE051430T2 (hu) * 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
ES2596254T3 (es) * 2009-12-18 2017-01-05 Sanofi Novedosos anticuerpos antagonistas y sus fragmentos Fab contra GPVI y usos de los mismos
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP3363812A1 (en) * 2011-06-23 2018-08-22 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
BR122017005075B1 (pt) * 2011-06-23 2022-09-20 Ablynx N.V Técnicas para prever, detectar e reduzir interferência de proteína não especifica em ensaios envolvendo domínios variáveis únicos de imunoglobulina
AU2012296961B2 (en) * 2011-08-17 2017-02-16 Glaxo Group Limited Modified proteins and peptides
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins

Also Published As

Publication number Publication date
EP2744822A2 (en) 2014-06-25
CN103917557B (zh) 2018-03-20
UA118833C2 (uk) 2019-03-25
AU2016277685B2 (en) 2019-03-28
KR102162413B1 (ko) 2020-10-07
MA35428B1 (fr) 2014-09-01
UY34254A (es) 2013-04-05
WO2013024059A3 (en) 2014-05-30
US10808040B2 (en) 2020-10-20
EA027160B1 (ru) 2017-06-30
AR087521A1 (es) 2014-03-26
CN108178800A (zh) 2018-06-19
JP6297976B2 (ja) 2018-03-20
KR20190113996A (ko) 2019-10-08
CN108178800B (zh) 2022-06-17
JP2018117623A (ja) 2018-08-02
AU2012296961A1 (en) 2014-03-13
EP2744822B1 (en) 2020-06-24
CN103917557A (zh) 2014-07-09
JP6979446B2 (ja) 2021-12-15
PE20141522A1 (es) 2014-11-17
AU2012296961B2 (en) 2017-02-16
HK1214281A1 (zh) 2016-07-22
ES2813432T3 (es) 2021-03-23
KR102143506B1 (ko) 2020-08-12
US20140227259A1 (en) 2014-08-14
EP3339322A3 (en) 2018-10-31
BR112014003679A2 (pt) 2017-03-07
AU2019201505A1 (en) 2019-03-28
TW201321405A (zh) 2013-06-01
EA201490262A1 (ru) 2014-09-30
PH12014500380A1 (en) 2022-05-02
MX2014001883A (es) 2014-05-27
JP2014525752A (ja) 2014-10-02
SG10201605891TA (en) 2016-09-29
WO2013024059A2 (en) 2013-02-21
JP2020054374A (ja) 2020-04-09
SG2014010482A (en) 2014-04-28
EP3339322A2 (en) 2018-06-27
DOP2014000029A (es) 2014-10-31
AU2016277685A1 (en) 2017-01-19
MY167125A (en) 2018-08-13
CA2845029A1 (en) 2013-02-21
US20210017293A1 (en) 2021-01-21
IL230918A0 (en) 2014-03-31
WO2013024059A9 (en) 2014-04-03
BR112014003679B1 (pt) 2022-08-30
EP2987806A2 (en) 2016-02-24
EP2987806A3 (en) 2016-07-13
NZ621203A (en) 2016-03-31
KR20140054262A (ko) 2014-05-08

Similar Documents

Publication Publication Date Title
CO7020851A2 (es) Proteínas y péptidos modificados
LTPA2019012I1 (lt) Plazmos kalikreiną surišantys baltymai
HK1200871A1 (en) Modified dna-binding proteins and uses thereof dna-
HRP20150241T1 (xx) Antikancerogeni fuzijski protein
EP2753635A4 (en) P53-ACTIVATING PEPTIDES
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
BR112014004902A2 (pt) peptídeos
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
EP2760471A4 (en) THERAPEUTIC PEPTIDES
DK2890402T3 (da) Modificerede aminosyrer omfattende en azidogruppe
BR112015003838A2 (pt) formulações de anticorpo e proteína
HUE055505T2 (hu) Anti-CGRP készítmények és alkalmazásuk
HK1209060A1 (zh) 內質蛋白的抗體及其用途
IL232645B (en) Recombinant proteins and their therapeutic uses
EP2688579A4 (en) CATIONIC AROMATIC PEPTIDES AND USES THEREOF
ME02224B (me) Antikancerski fuzioni protein
BR112013017488A2 (pt) peptídeos imunogênicos multiméricos e monoméricos
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
FI20116212L (fi) Polypeptidi
EP2812347A4 (en) PEPTIDE INDUCING AUTOPHAGIA
HK1251236A1 (zh) Topk肽和包含它們的疫苗
BR112013024323A2 (pt) peptídeos neuroprotetores
EP2742153A4 (en) PROTEIN AND PEPTIDE LIBRARIES
CL2014002180A1 (es) Peptidos antomicrobianos